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SUMMARY
Mild hypothermia (MH) and retroperfusion are 2 techniques proposed to reduce infarct size due to myocardial infarction. The authors evaluated the effects of focal MH combined with selective coronary venous autoretroperfusion (SARP) as an acute cardioprotective modality before percutaneous coronary intervention (PCI) in a swine model of left ventricular myocardial infarction. Significant reduction in infarct size with preservation of cardiac function and cardiomyocyte viability were achieved. The authors propose that SARP alone or in combination with MH may provide a clinically relevant percutaneous short-term option of cardiac support to high- (1) . These conditions usually present themselves with a high incidence of cardiogenic shock (3) , which places these patients in a group at high surgical risk for revascularization, along with a group of patients with multiple comorbidities such as stroke, diabetes, heart failure with low ejection fraction (EF), cardiac arrhythmias, and advanced age (4) . Temporary percutaneous left ventricular (LV) assist devices such as the Impella Maryland) have been said to offer hemodynamic support (via improved perfusion) to this group of patients, allowing the interventional cardiologists to undertake these high-risk procedures (5) . A recent systematic review, however, of 20 studies (4 small randomized controlled trials and 16 observational studies) evaluating the safety and efficacy of the Impella and the IABP for high-risk percutaneous coronary interventions (PCIs) concluded that, although the Impella appeared to offer better hemodynamic support and procedural characteristics than the IABP, the number of available studies supporting the effectiveness of either device was small, and all observational studies had a high or critical risk of bias (4).
Furthermore
, it now appears that the IABP for cardiogenic shock offers no benefit, and it is no better than placebo (6) . Whichever the case may be, this type of cardioprotection is ineffective in patients with severely occluded coronary arteries.
Mild hypothermia (MH), defined as a temperature of 32 C to 35.9 C, has been reported to provide cardioprotection and decrease in infarct size following a STEMI by reducing myocardial metabolic demand, free radical production, and platelet aggregation (7) .
Clinical translation of these cardioprotective results, however, has not been successful because of an inability to locally cool the ischemic region before PCI (8, 9) . Unlike the obstructed coronary arterial system, the coronary venous system remains unobstructed and thus has great potential for therapy delivery (retrograde delivery of arterial blood flowretroperfusion-with and without MH). To date, therapeutic retroperfusion has not been adopted clinically (although the concept was introduced more than a century ago) because complicated equipment is required to regulate perfusion to prevent damage to the entire coronary venous system when exposed to arterial pressures (9) .
The purpose of the present study was to evaluate the effects of selective autoretroperfusion (SARP) and MH-SARP on offering temporary myocardial support (i.e., reduced demand through hypothermia and increased perfusion through SARP) when applied following coronary artery occlusion before PCI. A novel SARP catheter (9, 10) regulates the pressure reaching the venous system to locally deliver either normothermic or cooled arterial blood to the ischemic region of the myocardium. The proposed strategy conferred cardioprotection during coronary occlusion in swine and warrants clinical translation for myocardial preservation in high-risk patients undergoing complex procedures. The SARP catheter was inserted through the right jugular vein, advanced into the coronary sinus, and then positioned in the great cardiac vein (GCV) between the base of the heart and the anterior interventricular sulcus. With all catheters in place, baseline measurements (echocardiography, blood sample collection, arterial pressure, and electrocardiogram recording) were taken before initiation of the procedure. The heart preparation at the end of the study has been described elsewhere (10) .
MH-SARP SYSTEM. The system was composed of an arterial access sheath, an extracorporeal Peltier cooling system used in conjunction with a stainless steel heat-transfer heat exchanger, an inline drug delivery port, a flow control mechanism, and the custom delivery SARP catheter. Arterial blood, shunted from the right carotid artery, passed via silicone tubing through the heat exchanger, and was then delivered to the GCV connected to the SARP catheter. The arterial blood was delivered into the GCV using the animal's own pulse pressure (i.e., autoretroperfusion) without the need of synchronized pumps.
In all 3 groups, the LAD artery was occluded for 60 min and then reperfused. In the MH-SARP and In analyses where an interaction between group and time was found to be significant, simple main effects were examined to look at group differences within each time point and to look at time differences within each group. The differences were considered significant at p < 0.05. Further, each outcome variable was considered a family, and a Bonferroni correction was used to cap the familywise error rate at 5%.
RESULTS
The hemodynamic parameters in the control, normothermia, and hypothermia groups at baseline, occlusion, retroperfusion, and reperfusion periods are summarized in Table 1 . Following the initiation of MH-SARP, the myocardial temperature in the subendocardium ( Figure 1A ) decreased from 35.9 C AE 0.8 C to 35.1 C AE 1.1 C in <4 min ( Figures 1A and 1B) .
Once MH-SARP treatment was terminated, the subendocardial temperature progressively increased to baseline levels in approximately 15 min ( Figure 1B) . A significant interaction between group and time was found for cTnI ( Figure 2D) MiR-1 ( Figure 3A) and miR-133a ( Figure 3B Figure 5D ) samples, which approximate healthy viable myocardium ( Figure 5A ).
Indices of cardiac metabolism with SARP and MH-SARP are shown in Figure 6 . A statistically 
DISCUSSION
We have shown that SARP, alone (10) Several animal and clinical studies (11, 12) have documented the beneficial effects of hypothermia to minimize infarct size following AMI. Hypothermia has also been reported to decrease cardiomyocyte apoptosis by decreasing activation of caspase-3 (13), an important mediator of apoptosis, which was reduced in the MH-SARP group as shown in Figure 5D .
Similarly, the beneficial effects of venous retroperfusion for the ischemic myocardium, with (14) and without (10,15) synchronized pumping have been largely investigated. In this study, we evaluated the adjunctive effects of both SARP (without the use of synchronized pumps) to enhance coronary perfusion, and MH to reduce demand as well as oxidative stress, as temporary percutaneous cardiac support before PCI. The reduction in the subendocardial temperature by 1 C did not add much value to the SARP procedure, although a larger decrease in temperature is expected in other regions of the myocardium such as the subepicardium. The small decrease in subendocardial for example, is minimally invasive but does not provide significant benefit to patients with severe cardiogenic shock with a systolic aortic pressure <60 mm Hg (18) . The TandemHeart seems to confer better results in this type of patients, but it is more invasive with greater vascular complications (19) . The Impella is the latest of the 3 LV assist devices and can increase cardiac output up to 5.0 l/min. The Impella unloads blood from the LV into the aorta, which increases coronary perfusion pressure (20) . It also decreases myocardial workload and metabolic consumption, which contributes to a reduction of infarct size in AMI (21) . As mentioned in the preceding text, however, these ventricular assist devices offer little protection to patients with obstructed coronary MH-SARP and SARP alone significantly reduced the incidence of ventricular arrhythmias during the reperfusion period, which appears to mirror outcomes in patients. The presence of arrhythmias has been attributed to attenuation of conduction, which usually occurs during ischemia and is pre-requisite for re-entry (24) . It has been postulated that MH prevents ischemia-induced conduction block and conduction velocity slowing by preserving gap junction coupling as well as sodium channel function (25) .
It is worth noting that large myocardial temperature gradients can cause severe arrhythmias due to the dispersion of the action potential (26) . On the other hand, in the presence of MH, arrhythmias may be completely abolished, which underscores the importance of the degree of hypothermia as an adjunctive therapy in myocardial ischemia. In our study, both MH-SARP and SARP alone significantly reduced the incidence of arrhythmic events post-reperfusion.
Following the initiation of SARP, an increase in effluent PO 2 was observed. This somewhat paradoxical finding suggests a reduced oxygen uptake, which may be the result of cell death or conversion to a glycolytic ischemic metabolism. Support for the latter is provided by marked increase in glucose uptake.
These data demonstrate that the onset of anaerobic which is on par with access to the sinus for lead implantation (27) , and hence, would not significantly delay the door-to-balloon time. Furthermore, any small delay to the door-to-balloon time is unlikely to affect outcomes (28) . 
